Talya Salz, PhD

Associate Attending Outcomes Research Scientist
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Talya Salz, PhD

Associate Attending Outcomes Research Scientist
Share
Share
Talya Salz, Associate Attending Outcomes Research Scientist

Office Phone

646-888-8231

Email

[email protected]

Education

University of North Carolina at Chapel Hill

Current Research Interests

Dr. Salz’s research aims to improve the quality of care for cancer survivors, focusing primarily on late effects after cancer treatment. Her research addresses survivorship interventions, including needs assessments, clinical intervention development, and effectiveness testing. She currently leads an American Cancer Society-funded trial to test the implementation and effectiveness of a web-based intervention for personalizing the ongoing care of head and neck cancer survivors. Another area of her research addresses risk factors for cardiovascular late effects among lymphoma survivors to guide cardiovascular preventive care for this vulnerable population. She also is investigating trends in pain management among cancer survivors, focusing on trends in opioid and cannabis use.

Publications

Selected peer-reviewed publications:

  1. Salz T, Oeffinger KC, McCabe MS, Layne TM, Bach PB. Survivorship care plans in research and practice. CA: A Cancer Journal for Clinicians. 2012 Jan 12. Epub 2012/01/14. PMCID: PMC3330140
  2. Salz T, Oeffinger KC, Lewis PR, Williams RL, Rhyne RL, Yeazel MW. Primary care providers’ needs and preferences for information about colorectal cancer survivorship care. Journal of the American Board of Family Medicine. 2012 Sep-Oct; 25: 635-51. PMCID: PMC3697120
  3. Salz T, McCabe MS, Onstad EE, Baxi SS, Deming RL, Franco RA, Glenn LA, Harper GR, Jumonville AJ, Payne RM, Peters EA, Salner AL, Schallenkamp JM, Williams SR, Yiee K, Oeffinger KC. Survivorship care plans: Is there buy-in from community oncology providers? Cancer. 2014 Mar 1;120(5):722-30. PMCID: PMC3949150
  4. Salz T, Baxi SS, Blinder VS, Elkin EB, Kemeny MM, McCabe MS, Moskowitz CS, Onstad EE, Saltz LB, Temple LK, Oeffinger KC. Colorectal cancer survivors’ needs and preferences for survivorship information. J Oncol Pract. 2014 Jul;10(4):e277-82. PMCID: PMC4094649
  5. Salz T, Baxi SS, Raghunathan N, Onstad EE, Freedman AN, Moskowitz CS, Dalton SO, Goodman KA, Johansen C, Matasar MJ, de Nully Brown P, Oeffinger KC, Vickers AJ. Are we ready to predict late effects? A systematic review of clinically useful prediction models. Eur J Cancer. 2015 Apr;51(6):758-66.

View a full listing of Talya Salz’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Talya Salz discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures
Related topics: